These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1016 related items for PubMed ID: 22371439

  • 1. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V.
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [Abstract] [Full Text] [Related]

  • 2. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 3. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.
    Clin Infect Dis; 2009 Nov 15; 49(10):1591-601. PubMed ID: 19842973
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
    Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF.
    J Acquir Immune Defic Syndr; 2010 Nov 15; 55(3):336-44. PubMed ID: 20739898
    [Abstract] [Full Text] [Related]

  • 6. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C, Nelson M, UK Collaborative HIV Cohort (CHIC) Study Group, UK HIV Drug Resistance Database (UK HDRD) Study Group.
    J Infect; 2014 Jan 15; 68(1):77-84. PubMed ID: 24055802
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Jan 15; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 10. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, Study 934 Team.
    J Acquir Immune Defic Syndr; 2009 Oct 01; 52(2):209-21. PubMed ID: 19644384
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 12. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K, HIV STAR Study Group.
    Antivir Ther; 2012 Jul 31; 17(7):1351-61. PubMed ID: 23075703
    [Abstract] [Full Text] [Related]

  • 13. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM, Arribas López JR.
    Expert Rev Anti Infect Ther; 2006 Aug 31; 4(4):523-35. PubMed ID: 17009933
    [Abstract] [Full Text] [Related]

  • 14. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
    Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M, ARCA Collaborative Group.
    AIDS; 2010 Apr 24; 24(7):1013-8. PubMed ID: 20124969
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec 24; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R, Hidalgo C, Ríos MJ, Rivero A, Muñoz L, Lozano F, Gutiérrez-Ravé V, Gálvez MC, del Arco A, Santos J.
    Eur J Clin Microbiol Infect Dis; 2009 Apr 24; 28(4):399-402. PubMed ID: 18841401
    [Abstract] [Full Text] [Related]

  • 20. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
    Blanco JL, Montaner JS, Marconi VC, Santoro MM, Campos-Loza AE, Shafer RW, Miller MD, Paredes R, Harrigan R, Nguyen ML, Perno CF, Gonzalez-Hernandez LA, Gatell JM.
    AIDS; 2014 Nov 13; 28(17):2531-9. PubMed ID: 25574957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.